SUNNYVALE, California - Large multi-center trial conducted in a community practice setting demonstrates comparable outcomes as trials conducted in predominantly tertiary academic centers
Clinical trial results presented at the Digestive Disease Week in Chicago today reveal that endoscopic radiofrequency ablation performed in a community practice setting is safe and effective for eradicating a pre-cancerous esophageal condition known as Barrett’s esophagus. The study is entitled, “Radiofrequency Ablation of Barrett Esophagus: Outcomes of 429 Patients from a Multi-center Community Practice Registry” and was presented today by Ronald E. Pruitt, M.D., Nashville, TN, at a scientific session sponsored by the American Society of Gastrointestinal Endoscopy.
The study’s author reported on 429 patients with Barrett’s esophagus, with and without advanced dysplasia (cellular signs of advanced progression towards cancer), who were treated with radiofrequency ablation using the HALO ablation system (BARRX Medical, Sunnyvale, CA) over the last 4 years. They report that the adverse event rate was favorable, with a low stricture risk (about 1%) and no serious adverse events. After an average of 2 ablation procedures and 20 month follow-up, 77% of patients were cured of their Barrett’s disease. For those patients that had baseline evidence of dysplasia, 100% had complete eradication of all signs of dysplasia.
“We believe that the results of our trial are unique and relevant to the scientific knowledge-base, as this is the largest patient experience reported to date and the first multi-center trial conducted at community practice centers for using radiofrequency ablation to eradicate Barrett’s esophagus,” said Dr. Pruitt. “Most importantly, we found that the safety and efficacy outcomes garnered in this clinical setting comport with those from reported trials conducted as predominantly academic tertiary referral centers.”
Study centers were comprised of large community practices with expertise in therapeutic endoscopy and the management of Barrett’s esophagus. Radiofrequency ablation was applied with a balloon-based circumferential device and an endoscope mounted focal device. Patients underwent biopsy sampling of tissue from the esophagus at regular intervals to determine if all Barrett’s disease had been eradicated. To be considered a “complete responder,” all biopsy samples had to be normal.
“This study is highly relevant and represents an important contribution to the science related to Barrett’s esophagus therapy,” commented David S. Utley, M.D., chief medical officer for BARRX Medical. “The study’s strengths lie in its large number of studied patients, relatively long follow-up and objective histology endpoints. This evidence suggests that ablative therapy can be delivered by the expert endoscopist in the community setting, with an expectation for comparable results as seen in prospective trials from tertiary referral centers.”
About BARRX Medical, Inc.
BARRX Medical, Inc. develops treatment solutions for Barrett’s esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue and allows regrowth of normal cells. The HALO90 System is the company’s second ablation product, which is mounted on the end of an endoscope and used to treat smaller, non-circumferential areas of disease.
A multi-center randomized, sham-controlled study, published in the New England Journal of Medicine, studied radiofrequency ablation applied in the highest risk Barrett’s population (those having dysplasia). The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and a significantly decreased the rate of disease progression and cancer development, as compared to the control group. In another study (AIM-II) published in Gastrointestinal Endoscopy, 98.4 percent of patients were Barrett’s-free after two and a half years of follow-up.
Both HALO systems are cleared by the FDA for use in the U.S. and both have CE Mark for use in Europe. More than 30,000 procedures have been performed in over 280 hospitals around the world. Based in Sunnyvale, Calif., BARRX Medical, Inc. was founded in 2000 and is privately-held. Additional information is available at www.barrx.com.
About Digestive Disease Week
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers, and academicians in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 30 - June 4, 2009 in Chicago, IL. The meeting presents approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research and technology.
Source: BARRX Medical, Inc.
Kevin Knight, +1-972-385-9384, Mobile, +1-214-732-9392, kmcinc at aol.com, for BARRX Medical, Inc., or Gregory A. Barrett of BARRX Medical, Inc., +1-408-328-7308, gbarrett at barrx.com
Related Press Releases
NeuroTherm is Awarded US Patent for Multi-lesion Radiofrequency GeneratorSeptember 22nd, 2009 WILMINGTON, Massachusetts -
NeuroTherm is pleased to be recognized by the United States Patent Office as the first company worldwide to develop and release a multiple output radiofrequency generator used in the treatment of chronic pain, ref. US Patent No.
A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain DisordersJuly 13th, 2009 TIRAT CARMEL, Israel -
- Ten-Patient Feasibility Study Shows Safety and Potential for Non-Invasive Deep Brain Ablation
InSightec Ltd. today announced that a team at the University Children's Hospital Zurich has completed a feasibility study testing the use of non-invasive transcranial MR-guided focused ultrasound surgery (MRgFUS) for the treatment of neuropathic pain.
Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser TherapyJune 16th, 2009 TEL AVIV, Israel - In-vivo Clinical Study Confirms the Efficacy of TriPollar(TM) Technology for Reducing Fat and neo Collagen Generation
A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the safety and efficacy of TriPollar(TM) technology in reducing fat and collagen remodeling. The peer reviewed paper entitled "Clinical and histopathological results following TriPollar(TM) radiofrequency skin treatments", authored by Dr.
Study Demonstrates Efficacy of Pitavastatin in Elderly PatientsJune 15th, 2009 BOSTON - Pitavastatin Represents Important Treatment Option for More Vulnerable Populations
New data presented today showed that pitavastatin is an effective treatment for the management of dyslipidaemia in elderly patients, with a similar safety and tolerability profile to low-dose pravastatin. The Phase III data were presented today by Kowa, at the XV International Symposium on Atherosclerosis in Boston.
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly PatientsJune 10th, 2009 SEATTLE - Neurim Pharmaceuticals (www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington.
Advance in Bowel Cancer Test ResearchJune 4th, 2009 SYDNEY - Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls. Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions.
Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal SurgeonsJune 2nd, 2009 SUNNYVALE, California - Radiofrequency ablation is durable after 2 years, compares favorably with endoscopic resection for advanced disease, and reduces the risk for cancer progression
Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as Barrett's esophagus. Among them, reports included durability outcomes from a randomized sham-controlled trial, safety and efficacy outcomes from a large U.S.
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer DevelopmentMay 27th, 2009 SUNNYVALE, California - Data show superiority of endoscopic ablation therapy using the HALO System for eradicating Barrett's esophagus in randomized, multicenter, sham controlled trial
Results from a clinical study published today in the New England Journal of Medicine reveal that ablative therapy using the HALO system (BARRX Medical, Inc.) is highly effective for complete eradication of a pre-cancerous condition of the esophagus called Barrett's esophagus afflicting more than 3.3 million Americans. Additionally, ablative therapy using the HALO system reduced the risk of progression to cancer in the highest risk cohort studied (compared to control) from 19.0% to 2.4%.
The Hidden Heart ProblemMay 26th, 2009 LONDON - YouGov Survey Reveals Low Awareness of Potentially Fatal Heart Condition That Affects Significant Number of People in UK
LONDON, May 27 /PRNewswire/ --
As many as 700,000 people in the UK suffer from a heart abnormality called arrhythmia, a potentially fatal condition, which the majority of Londoners have never heard of - according to a recent survey conducted by YouGov[1]. Many of the deaths associated with arrhythmias could be prevented due to advances in the identification and treatment of high risk patients.
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar ABMay 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease.
Related News
Childhood kidney disorder may persist into adulthood with long-term complicationsSeptember 25th, 2009 WASHINGTON - A childhood kidney disorder, which was believed to disappear after puberty, is likely to persist into adulthood and cause significant long-term complications, reveals a new study. The study's researchers suggest that better treatment options are needed for children with the disorder, called minimal change nephrotic syndrome.
"Male Pill" can provide effective contraceptionMay 5th, 2009 WASHINGTON - A "male Pill" tested by scientists has proved to be as good as its female equivalent after a major study found only one in 100 males using the injections conceived a child. According to researchers, the testosterone injection could revolutionise family planning methods.
Chronic diseases linked to higher levels of depressionJanuary 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects.
Injectable testosterone - way to effective male contraceptionMay 5th, 2009 WASHINGTON - Injectable testosterone could be the way to male contraception, that is effective, reversible, and minus serious short-term side-effects, according to a new study. 'For couples who can not, or prefer not to, use only female-oriented contraception, options have been limited to vasectomy, condom and withdrawal,' said Yi-Qun Gu, National Research Institute for Family Planning (NRIFP) in Beijing.
Fast acting erectile disorder drug goes on trial againFebruary 15th, 2009 WASHINGTON - A new fast-acting oral drug for erectile dysfunction (ED) is ready for a crucial trial phase. It's going to be a multicentre, randomised, double-blind, placebo-controlled trial that will evaluate the safety and efficacy of Avanafil in the treatment of ED in men with type-1 or type-2 diabetes.
Vitamin D deficiency may worsen chronic painMarch 21st, 2009 WASHINGTON - Vitamin D deficiency might worsen the condition of people suffering from chronic pain, according to a new study. The research from Mayo Clinic has found a link between inadequate vitamin D levels and the amount of narcotic medication taken by patients who have chronic pain.
Novel drug offers highly effective treatment for blood disorderMarch 21st, 2009 LONDON - An international team of researchers has found a new drug that can prove to be an effective treatment option for thrombocytopenic purpura (ITP), a chronic blood disorder. Thrombocytopenic purpura (ITP) is an autoimmune disease that dramatically reduces the number of platelets in their blood - causing bruises, nosebleeds and, rarely, life-threatening brain hemorrhages.
Study: Half of drug addicts quit after 6 months of treatment, but long-term care neededOctober 1st, 2009 Half of addicts quit after 6 months of treatmentLONDON — About half of heroin and crack cocaine addicts in England's treatment programs quit the drugs after six months, a new study says. Experts warned, however, that the danger of relapse means permanently kicking the habit probably requires ongoing care.
Novel target for migraine prevention identifiedApril 29th, 2009 WASHINGTON - Researchers have found a potential target for developing new treatment for acute migraine attacks. The new research by Addex Pharmaceuticals showed that targeting glutamate receptor 'mGluR5', the most common neurotransmitter in the brain, could prevent migraines.
Once-a-day oral medication lowers ADHD symptoms in kidsJuly 23rd, 2009 WASHINGTON - An oral stimulant given once daily has been found effective in reducing Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children for upto 13 hours, say researchers. Vyvanse (lisdexamfetamine dimesylate) CII significantly has been found to lower (ADHD) in children aged 6 to 12 up to 13 hours after administration.
